imjudo
astrazeneca ab - tremelimumab - carcinoma, hepatocellular - antineoplastiset aineet - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.
mysoline 250 mg tabletti
astrazeneca oy - primidonum - tabletti - 250 mg - primidoni
citanest 10 mg/ml injektioneste, liuos
astrazeneca oy - prilocaini hydrochloridum - injektioneste, liuos - 10 mg/ml - prilokaiini
xylocain 5 % voide
astrazeneca oy - lidocainum - voide - 5 % - lidokaiini
xylocain 5 mg/ml kurlausvesi
astrazeneca oy - lidocaini hydrochloridum - kurlausvesi - 5 mg/ml - lidokaiini
fulcin 125 mg tabletti
astrazeneca uk limited - griseofulvinum - tabletti - 125 mg - griseofulviini
avlosulfon 100 mg tabletti
astrazeneca uk limited - dapsonum - tabletti - 100 mg - dapsoni
ekvacillin injektio/infuusiokuiva-aine, liuosta varten
astrazeneca oy - cloxacillinum natricum - injektio/infuusiokuiva-aine, liuosta varten - kloksasilliini
inderal 1 mg/ml injektioneste
astrazeneca uk limited - propranololi hydrochloridum - injektioneste - 1 mg/ml - propranololi
inderal 10 mg tabletti, kalvopäällysteinen
astrazeneca oy - propranololi hydrochloridum - tabletti, kalvopäällysteinen - 10 mg - propranololi